301096 百诚医药
已收盘 05-12 15:00:00
资讯
新帖
简况
百诚医药涨5.52%，东吴证券一周前给出“买入”评级
证券之星 · 05-11 16:38
百诚医药涨5.52%，东吴证券一周前给出“买入”评级
股市必读：百诚医药年报 - 第四季度单季净利润同比增长50.35%
证券之星 · 04-27
股市必读：百诚医药年报 - 第四季度单季净利润同比增长50.35%
百诚医药（301096）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 04-25
百诚医药（301096）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
图解百诚医药年报：第四季度单季净利润同比增长50.35%
证券之星 · 04-24
图解百诚医药年报：第四季度单季净利润同比增长50.35%
百诚医药（301096）披露2025年度利润分配方案：拟不派息不送股不转增，4月23日股价下跌0.83%
证券之星 · 04-23
百诚医药（301096）披露2025年度利润分配方案：拟不派息不送股不转增，4月23日股价下跌0.83%
股市必读：4月17日百诚医药发生1笔大宗交易 成交金额720.77万元
证券之星 · 04-20
股市必读：4月17日百诚医药发生1笔大宗交易 成交金额720.77万元
4月17日百诚医药发生1笔大宗交易 成交金额720.77万元
证券之星 · 04-17
4月17日百诚医药发生1笔大宗交易 成交金额720.77万元
4月1日百诚医药涨6.20%，金元顺安桉盛债券A基金重仓该股
证券之星 · 04-01
4月1日百诚医药涨6.20%，金元顺安桉盛债券A基金重仓该股
3月10日百诚医药涨7.28%，金元顺安桉盛债券A基金重仓该股
中金财经 · 03-10
3月10日百诚医药涨7.28%，金元顺安桉盛债券A基金重仓该股
股市必读：百诚医药（301096）今年截至3月3日累计跌幅已超20%
证券之星 · 03-04
股市必读：百诚医药（301096）今年截至3月3日累计跌幅已超20%
百诚医药（301096）披露全资子公司完成工商设立登记公告，2月5日股价下跌2.55%
证券之星 · 02-05
百诚医药（301096）披露全资子公司完成工商设立登记公告，2月5日股价下跌2.55%
股市必读：百诚医药（301096）预计2025年全年扣非后净利润亏损7900万元至1.1亿元
证券之星 · 02-02
股市必读：百诚医药（301096）预计2025年全年扣非后净利润亏损7900万元至1.1亿元
百诚医药（301096）披露2025年度业绩预告，1月30日股价下跌0.87%
证券之星 · 01-30
百诚医药（301096）披露2025年度业绩预告，1月30日股价下跌0.87%
百诚医药（301096）披露投资设立全资子公司公告，1月29日股价下跌2.11%
证券之星 · 01-29
百诚医药（301096）披露投资设立全资子公司公告，1月29日股价下跌2.11%
1月26日百诚医药发生2笔大宗交易 成交金额1320.48万元
证券之星 · 01-26
1月26日百诚医药发生2笔大宗交易 成交金额1320.48万元
百诚医药（301096）披露使用部分闲置募集资金暂时补充流动资金，12月19日股价上涨1.06%
证券之星 · 2025-12-19
百诚医药（301096）披露使用部分闲置募集资金暂时补充流动资金，12月19日股价上涨1.06%
百诚医药最新公告：员工战略配售资管计划拟减持不超0.5077%公司股份
证券之星 · 2025-12-14
百诚医药最新公告：员工战略配售资管计划拟减持不超0.5077%公司股份
百诚医药：12月1日高管宋博凡、严洪兵减持股份合计1100股
证券之星 · 2025-12-02
百诚医药：12月1日高管宋博凡、严洪兵减持股份合计1100股
百诚医药：11月21日高管严洪兵减持股份合计1000股
证券之星 · 2025-11-24
百诚医药：11月21日高管严洪兵减持股份合计1000股
百诚医药（301096）发布董事会议事规则，11月21日股价下跌4.33%
证券之星 · 2025-11-21
百诚医药（301096）发布董事会议事规则，11月21日股价下跌4.33%
加载更多
公司概况
公司名称：
杭州百诚医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-12-20
主营业务：
杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供医药技术受托研发服务（CRO业务）、研发技术成果转化服务、定制研发生产服务（CDMO）。公司的主要产品是药学研究、临床试验、注册申报、研发技术成果转化、定制研发生产服务（CDMO）、自主创新药物研发、受托创新药物研发。公司先后获得“国家高新技术企业”“省级重点企业研究院”“省级技术中心”等荣誉。
发行价格：
79.60
{"stockData":{"symbol":"301096","market":"SZ","secType":"STK","nameCN":"百诚医药","latestPrice":63.53,"timestamp":1778569410000,"preClose":63.82,"halted":0,"volume":2755700,"delay":0,"changeRate":-0.0045,"floatShares":83090000,"shares":109000000,"eps":-0.4705,"marketStatus":"已收盘","change":-0.29,"latestTime":"05-12 15:00:00","open":63.82,"high":65.18,"low":62.69,"amount":176000000,"amplitude":0.039,"askPrice":63.54,"askSize":16,"bidPrice":63.53,"bidSize":23,"shortable":0,"etf":0,"ttmEps":-0.4705,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":5,"adr":0,"adjPreClose":63.82,"symbolType":"stock","openAndCloseTimeList":[[1778549400000,1778556600000],[1778562000000,1778569200000]],"highLimit":70.2,"lowLimit":57.44,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":109228284,"isCdr":false,"pbRate":2.79,"roa":"--","roe":"0.51%","epsLYR":-0.83,"committee":-0.547619,"marketValue":6939000000,"turnoverRate":0.0332,"status":1,"floatMarketCap":5279000000},"requestUrl":"/m/hq/s/301096","defaultTab":"news","newsList":[{"id":"2634840943","title":"百诚医药涨5.52%，东吴证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634840943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634840943?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:38","pubTimestamp":1778488730,"startTime":"0","endTime":"0","summary":"今日百诚医药（301096）涨5.52%，收盘报63.82元。2026年4月29日，东吴证券研究员朱国广,苏丰,邹行健发布了对百诚医药的研报《2025年报&2026一季报点评：26Q1利润超预期，创新管线持续推进》，该研报对百诚医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为69.92%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为西部证券的吴天昊。百诚医药（301096）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100022215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630486335","title":"股市必读：百诚医药年报 - 第四季度单季净利润同比增长50.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630486335","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630486335?lang=zh_cn&edition=full","pubTime":"2026-04-27 02:17","pubTimestamp":1777227428,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动近日百诚医药披露，截至2026年3月31日公司股东户数为1.12万户，较12月31日增加106.0户，增幅为0.95%。2025年内部控制审计报告天健会计师事务所对杭州百诚医药科技股份有限公司截至2025年12月31日的财务报告内部控制有效性进行了审计。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630873953","title":"百诚医药（301096）2026年一季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2630873953","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630873953?lang=zh_cn&edition=full","pubTime":"2026-04-25 06:35","pubTimestamp":1777070134,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百诚医药发布2026年一季报。截至本报告期末，公司营业总收入1.6亿元，同比上升24.65%，归母净利润1281.25万元，同比上升148.91%。本报告期百诚医药盈利能力上升，毛利率同比增幅21.35%，净利率同比增幅139.24%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500021918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629514028","title":"图解百诚医药年报：第四季度单季净利润同比增长50.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629514028","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629514028?lang=zh_cn&edition=full","pubTime":"2026-04-24 01:04","pubTimestamp":1776963861,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药2025年年报显示，当年度公司主营收入6.78亿元，同比下降15.45%；归母净利润-9039.55万元，同比下降71.39%；扣非净利润-1.03亿元，同比下降41.96%；其中2025年第四季度，公司单季度主营收入1.68亿元，同比上升108.97%；单季度归母净利润-9651.97万元，同比上升50.35%；单季度扣非净利润-8918.95万元，同比上升54.87%；负债率32.48%，投资收益-1179.68万元，财务费用1803.26万元，毛利率39.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400002669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629971858","title":"百诚医药（301096）披露2025年度利润分配方案：拟不派息不送股不转增，4月23日股价下跌0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629971858","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629971858?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:22","pubTimestamp":1776954144,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，百诚医药报收于57.19元，较前一交易日下跌0.83%，最新总市值为62.47亿元。近日，杭州百诚医药科技股份有限公司披露《关于公司2025年度利润分配方案的公告》。公告显示，公司于2026年4月23日召开第四届董事会第十次会议，审议通过《关于公司2025年度利润分配方案的议案》，该议案尚需提交2025年年度股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300062526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628793401","title":"股市必读：4月17日百诚医药发生1笔大宗交易 成交金额720.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628793401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628793401?lang=zh_cn&edition=full","pubTime":"2026-04-20 03:09","pubTimestamp":1776625748,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，百诚医药报收于57.94元，下跌0.43%，换手率3.35%，成交量2.78万手，成交额1.61亿元。当日关注点来自交易信息汇总：4月17日主力资金净流出1241.2万元，游资资金净流入1408.53万元。大宗交易4月17日百诚医药发生1笔大宗交易，成交金额720.77万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000001112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628710132","title":"4月17日百诚医药发生1笔大宗交易 成交金额720.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628710132","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628710132?lang=zh_cn&edition=full","pubTime":"2026-04-17 17:08","pubTimestamp":1776416902,"startTime":"0","endTime":"0","summary":"证券之星消息，4月17日百诚医药发生大宗交易，交易数据如下：大宗交易成交价格57.94元，成交12.44万股，成交金额720.77万元，买方营业部为信达证券股份有限公司仙居庆丰街证券营业部，卖方营业部为南京证券股份有限公司台州桔源街证券营业部。近三个月该股共发生4笔大宗交易，合计成交4950.0手，折价成交3笔。该股近期无解禁股上市。截至2026年4月17日收盘，百诚医药报收于57.94元，下跌0.43%，换手率3.35%，成交量2.78万手，成交额1.61亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700031903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624362595","title":"4月1日百诚医药涨6.20%，金元顺安桉盛债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624362595","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624362595?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:19","pubTimestamp":1775031544,"startTime":"0","endTime":"0","summary":"证券之星消息，4月1日百诚医药涨6.20%，收盘报53.99元，换手率5.0%，成交量4.14万手，成交额2.19亿元。重仓百诚医药的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为53.84。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为金元顺安基金的金元顺安桉盛债券A。该公募基金现任基金经理为郭建新 韩辰尧 李海瑞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100029173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618331933","title":"3月10日百诚医药涨7.28%，金元顺安桉盛债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618331933","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618331933?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:59","pubTimestamp":1773133168,"startTime":"0","endTime":"0","summary":"证券之星消息，3月10日百诚医药涨7.28%，收盘报52.17元，换手率6.06%，成交量5.01万手，成交额2.56亿元。重仓百诚医药的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为53.84。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为金元顺安基金的金元顺安桉盛债券A。该公募基金现任基金经理为郭建新 韩辰尧 李海瑞。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/10/20260310600179.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/10/20260310600179.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260310/32057349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616373614","title":"股市必读：百诚医药（301096）今年截至3月3日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616373614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616373614?lang=zh_cn&edition=full","pubTime":"2026-03-04 02:28","pubTimestamp":1772562493,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，百诚医药报收于43.89元，下跌4.79%，换手率3.82%，成交量3.16万手，成交额1.41亿元。交易信息汇总股价提醒3月3日百诚医药收盘报43.89元，跌4.79%，当日成交315.88万元。该股已连续4日下跌，当年累计跌幅22.62%。前10个交易日中，主力资金累计净流出1797.25万元，股价累计下跌11.1%；融资余额累计减少2337.2万元，融券余量累计减少400股。近90天内共有3家机构给予买入评级，目标均价为53.84元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400001369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609301484","title":"百诚医药（301096）披露全资子公司完成工商设立登记公告，2月5日股价下跌2.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609301484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609301484?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:39","pubTimestamp":1770302355,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，百诚医药报收于49.61元，较前一交易日下跌2.55%，最新总市值为54.19亿元。该股当日开盘50.8元，最高50.93元，最低49.35元，成交额达8882.71万元，换手率为2.15%。公司于2026年2月5日发布《关于全资子公司完成工商设立登记的公告》。公告显示，杭州百诚医药科技股份有限公司于2026年1月29日召开董事会，审议通过设立全资子公司浙江旭沛医药科技有限公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500039879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608884863","title":"股市必读：百诚医药（301096）预计2025年全年扣非后净利润亏损7900万元至1.1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608884863","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608884863?lang=zh_cn&edition=full","pubTime":"2026-02-02 05:09","pubTimestamp":1769980152,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，百诚医药报收于51.41元，下跌0.87%，换手率2.58%，成交量2.13万手，成交额1.11亿元。百诚医药发布业绩预告，预计2025年全年归属净利润亏损6600万元至9600万元。公司公告汇总2025年度业绩预告杭州百诚医药科技股份有限公司预计2025年度归属于上市公司股东的净利润亏损6,600万元至9,600万元，上年同期亏损5,274.28万元；扣除非经常性损益后的净利润亏损7,900万元至11,000万元，上年同期亏损7,263.18万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607047586","title":"百诚医药（301096）披露2025年度业绩预告，1月30日股价下跌0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607047586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607047586?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:39","pubTimestamp":1769787552,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，百诚医药报收于51.41元，较前一交易日下跌0.87%，最新总市值为56.15亿元。该股当日开盘51.85元，最高53.27元，最低51.1元，成交额达1.11亿元，换手率为2.58%。公司于2026年1月30日披露《2025年度业绩预告》。公告显示，杭州百诚医药科技股份有限公司预计2025年度归属于上市公司股东的净利润亏损6,600万元至9,600万元，上年同期亏损5,274.28万元；扣除非经常性损益后的净利润亏损7,900万元至11,000万元，上年同期亏损7,263.18万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607303542","title":"百诚医药（301096）披露投资设立全资子公司公告，1月29日股价下跌2.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607303542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607303542?lang=zh_cn&edition=full","pubTime":"2026-01-29 22:33","pubTimestamp":1769697196,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，百诚医药报收于51.86元，较前一交易日下跌2.11%，最新总市值为56.65亿元。该股当日开盘53.01元，最高53.35元，最低51.8元，成交额达1.17亿元，换手率为2.71%。百诚医药于2026年1月29日发布《关于投资设立全资子公司的公告》。公告显示，公司审议通过设立全资子公司浙江旭沛医药科技有限公司，以临平政工出〔2023〕26号文所涉宗地的土地使用权和在建工程评估作价5,849.94万元出资，持股100%，注册资本1,000万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900043707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606219887","title":"1月26日百诚医药发生2笔大宗交易 成交金额1320.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606219887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606219887?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:17","pubTimestamp":1769422660,"startTime":"0","endTime":"0","summary":"证券之星消息，1月26日百诚医药发生大宗交易，交易数据如下：近三个月该股共发生2笔大宗交易，合计成交2358.0手，折价成交2笔。该股近期无解禁股上市。截至2026年1月26日收盘，百诚医药(301096)报收于56.03元，下跌3.15%，换手率3.87%，成交量3.2万手，成交额1.81亿元。该股最近90天内共有4家机构给出评级，买入评级4家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600024751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592419865","title":"百诚医药（301096）披露使用部分闲置募集资金暂时补充流动资金，12月19日股价上涨1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592419865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592419865?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:26","pubTimestamp":1766154415,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘，百诚医药报收于54.12元，较前一交易日上涨1.06%，最新总市值为59.11亿元。公司近日发布公告称，于2025年12月19日召开第四届董事会第七次会议，审议通过使用不超过13,970万元的闲置募集资金暂时补充流动资金，使用期限自董事会审议通过之日起不超过12个月，到期将归还至募集资金专户。董事会同意新开设募集资金专项账户，并签署三方监管协议。保荐机构国金证券对公司本次补流事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591650670","title":"百诚医药最新公告：员工战略配售资管计划拟减持不超0.5077%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591650670","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591650670?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:20","pubTimestamp":1765700401,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，持有公司1.0425%股份的股东富诚海富资管—杭州银行—富诚海富通百诚医药员工参与创业板战略配售集合资产管理计划（简称“员工战略配售资管计划”）拟以大宗交易方式或集中竞价交易方式减持本公司股份不超过55.06万股（占公司总股本的0.5077%）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121400002945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588053246","title":"百诚医药：12月1日高管宋博凡、严洪兵减持股份合计1100股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053246","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588053246?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:03","pubTimestamp":1764680630,"startTime":"0","endTime":"0","summary":"证券之星消息，根据12月2日市场公开信息、上市公司公告及交易所披露数据整理，百诚医药最新董监高及相关人员股份变动情况：2025年12月1日公司董事宋博凡、董事严洪兵共减持公司股份1100.0股，占公司总股本为0.001%。变动期间公司股价上涨0.82%，12月1日当日收盘报54.15元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200037357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585462458","title":"百诚医药：11月21日高管严洪兵减持股份合计1000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462458","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585462458?lang=zh_cn&edition=full","pubTime":"2025-11-24 21:02","pubTimestamp":1763989368,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月24日市场公开信息、上市公司公告及交易所披露数据整理，百诚医药最新董监高及相关人员股份变动情况：2025年11月21日公司董事严洪兵共减持公司股份1000.0股，占公司总股本为0.0009%。变动期间公司股价下跌4.33%，11月21日当日收盘报48.8元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400032858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585149509","title":"百诚医药（301096）发布董事会议事规则，11月21日股价下跌4.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585149509","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585149509?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:26","pubTimestamp":1763735187,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，百诚医药报收于48.8元，较前一交易日下跌4.33%，最新总市值为53.3亿元。该股当日开盘50.88元，最高51.23元，最低48.8元，成交额达1.36亿元，换手率为3.31%。近日，杭州百诚医药科技股份有限公司发布《董事会议事规则》，明确董事会的组成、职权及议事决策程序。根据公告，董事会由9名董事组成，包括3名独立董事和1名职工代表董事，设董事长1名为法定代表人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778603966290,"stockEarnings":[{"period":"1week","weight":0.0849},{"period":"1month","weight":0.1587},{"period":"3month","weight":0.2879},{"period":"6month","weight":0.1608},{"period":"1year","weight":0.8183},{"period":"ytd","weight":0.1118}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0573},{"period":"3month","weight":0.02},{"period":"6month","weight":0.0459},{"period":"1year","weight":0.2509},{"period":"ytd","weight":0.0619}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州百诚医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"11216人(较上一季度增加0.95%)","perCapita":"7408股","listingDate":"2021-12-20","address":"浙江省杭州市临平区临平街道绿洲路159号","registeredCapital":"10922万元","survey":" 杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供医药技术受托研发服务（CRO业务）、研发技术成果转化服务、定制研发生产服务（CDMO）。公司的主要产品是药学研究、临床试验、注册申报、研发技术成果转化、定制研发生产服务（CDMO）、自主创新药物研发、受托创新药物研发。公司先后获得“国家高新技术企业”“省级重点企业研究院”“省级技术中心”等荣誉。","listedPrice":79.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百诚医药,301096,百诚医药股票,百诚医药股票老虎,百诚医药股票老虎国际,百诚医药行情,百诚医药股票行情,百诚医药股价,百诚医药股市,百诚医药股票价格,百诚医药股票交易,百诚医药股票购买,百诚医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}